Immunic, Inc.
IMUX
NASDAQ·Healthcare·Biotechnology·Mkt cap $178.6M
$13.11
▲ +2.74%
P/E
-2.74
Mkt Cap
$178.6M
52-Wk Range
$5.06–$17.43
52-Week Range
$5.06 - $17.43
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 58.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Selective oral immunology drug formulations with improved bioavailability
- Proprietary mechanism of action targeting multiple inflammatory pathways
- Advanced clinical pipeline with Phase 2 data supporting efficacy
- Diversified indication strategy reducing single-program risk
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Phase 2 clinical trial progression and positive efficacy data readouts
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+8.7% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying IMUX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 11, 2026
Reported EPS of -$0.80 vs -$1.16 consensus (+31.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+31.0%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
5 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
—
Latest: Roth Capital · Sep 1, 2026
vs Industry
How IMUX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related